Neurol. praxi. 2015;16(4):209-214

Treatment of movement impairment in Huntington΄s disease

MUDr. Jiří Klempíř, Ph.D., prof. MUDr. Jan Roth, CSc.
Neurologická klinika a Centrum klinických neurověd Univerzita Karlova v Praze, 1. LF a VFN v Praze

Huntington´s disease (HD) is the autosomal dominantly inherited progressive neurodegenerative disease. The clinical picture of HD is characterized by motor symptoms, behavioral changes and cognitive decline. The medication of HD is purely symptomatic, no causative or disease-modifying therapies are available. The degree of choreatic dyskinesias can be ameliorated by antagonists of postsynaptic dopamine receptors – antipsychotics (tiapride, risperidone, haloperidol etc.) or depletors of dopamine (tetrabenazine). Dystonic posturing could be improved by amantadine. In rare juvenile cases with dominant rigidity and akinesia amantadine or levodopa could be effective. Side effects, such as sedation, the negative impact on voluntary movements, cognitive functioning and quality of life, should always be taken into account, assessed and carefully monitored. The authors provide personal experiences with the treatment of motor impairment in HD.

Keywords: Huntington´s disease, chorea, dyskinesia, postural instability, tiapride, risperidone, haloperidol, tetrabenazine, amantadine

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klempíř J, Roth J. Treatment of movement impairment in Huntington΄s disease. Neurol. praxi. 2015;16(4):209-214.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012; 79: 597-603. Go to original source... Go to PubMed...
    2. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988; 38: 84-88. Go to original source... Go to PubMed...
    3. Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr 2011; 3: RRN1260. Go to original source...
    4. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999; 19: 101-103. Go to original source... Go to PubMed...
    5. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9: 329-393. Go to original source...
    6. Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators. Natural history of Huntington disease. JAMA Neurol 2013; 70: 1520-1530.
    7. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry 2008; 20: 1-3. Go to original source... Go to PubMed...
    8. Hunter C, Wang A, Vuong K. Age-related tolerability of tetrabenazine. Mov Disord. 2002; 17(Suppl 5): S41. Go to original source... Go to PubMed...
    9. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358-362. Go to original source...
    10. Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome: literature review and case series report. BMC Psychiatry 2012; 12: 214. Go to original source...
    11. Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA; Researchers of the PREDICT-HD Huntington's Study Group. Tracking motor impairments in the progression of Huntington's disease. Mov Disord 2014; 29: 311-319. Go to original source... Go to PubMed...
    12. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974; 1: 393-394. Go to original source... Go to PubMed...
    13. Magnet MK, Bonelli RM, Kapfhammer HP. Amantadine in the akinetic-rigid variant of Huntington's disease. Ann Pharmacother. 2004; 38: 1194-1196. Go to original source... Go to PubMed...
    14. Margolis RL. Tetrabenazine, depression and suicide: good news. J Huntingtons Dis 2014; 3: 137-138. Go to original source...
    15. Mattes JA. Risperidone: how good is the evidence for efficacy? Schizophr Bull. 1997; 23: 155-161. Go to original source... Go to PubMed...
    16. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009; 3: CD006456. Go to original source...
    17. Niemegeers CJ, Laduron PM. Pharmacology and biochemistry of haloperidol. Proc R Soc Med 1976; 69(Suppl 1): 3-8. Go to original source...
    18. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004; 27: 230-233. Go to original source... Go to PubMed...
    19. Parkes D. Amantadine. Adv Drug Res 1974; 8: 11-81. Go to PubMed...
    20. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976; 1: 225-227. Go to original source... Go to PubMed...
    21. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry. 1998; 65: 577-579. Go to original source...
    22. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013; 7: 1329-1340. Go to original source... Go to PubMed...
    23. Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord 2013; 28: 1030-1033. Go to original source... Go to PubMed...
    24. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000; 68: 238-241. Go to original source...
    25. Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982; 65: 45-50. Go to original source... Go to PubMed...
    26. Roth J. Huntingtonova nemoc. Cesk Slov Neurol N 2010; 106: 107-123.
    27. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R. The preclinical pharmacologic profile of tiapride. Eur Psychiatry 2001; 16 Suppl 1: 29-34. Go to original source...
    28. Umbricht D, Kane JM. Risperidone: efficacy and safety. Schizophr Bull 1995; 21(4): 593-606. Go to original source... Go to PubMed...
    29. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59: 694-9. Go to original source... Go to PubMed...
    30. van Vugt JP, Piet KK, Vink LJ, Siesling S, Zwinderman AH, Middelkoop HA, Roos RA. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up. Mov Disord 2004; 19: 285-97. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.